Press Releases

December 7, 2021

Non Regulatory

SynAct Pharma’s board and management extend lock-up agreements

December 2, 2021

Non Regulatory

SynAct Pharma announces additional data from the BEGIN study

December 1, 2021

Non Regulatory

SynAct Pharma strengthens its patent portfolio for AP1189 following an Intention to Grant from the European Patent Office

November 23, 2021

Non Regulatory

SynAct Pharma reports positive PK data on AP1189 tablets

November 19, 2021

Non Regulatory

SynAct Pharma announces Nomination Committee in respect of AGM 2022

November 11, 2021

Non Regulatory

SynAct Pharma takes advantage of new toxicology results and new tablet formulation to re-design and optimize the study programme with AP1189 in Nephrotic Syndrome

November 5, 2021

Non Regulatory

AP1189 can be dosed for three months in future clinical studies

October 25, 2021

Non Regulatory

SynAct Pharma completes dosing in the BEGIN study

October 15, 2021

Non Regulatory

SynAct Pharma doses first subject in study with new AP1189 tablets

July 7, 2021

Announcing additional Data from the Phase 2a Trial of AP1189 in Covid-19 Infected Patients

February 12, 2021

Non Regulatory

Year-end Report 2020